Blockage of TIM-3 relieves lupus nephritis by expanding Treg cells and promoting their suppressive capacity in MRL/lpr mice

Yasin-Abdi Saed,Yan-fang Gao,Yuan-yue Lu,Xiu-zhao Fan,Yan-hong Wang,Ji-hua Tian,Rong-shan Li,Xiao-shuang Zhou
DOI: https://doi.org/10.1016/j.intimp.2022.108971
IF: 5.714
2022-06-30
International Immunopharmacology
Abstract:T Cell Immunoglobulin and Mucin Containing Protein-3 (TIM-3) is an important immune checkpoint protein that is expressed in Tregs and affects their function. However, the expression and role of TIM-3 in modulating regulatory T cells (Tregs) in lupus nephritis (LN) are still unknown. In this study, we found that the percentage of TIM-3 + cells among spleen lymphocytes, CD4 + T cells and Tregs was higher in MRL/lpr mice than in MpJ mice. TIM-3 high CD4 + T cells and TIM-3 high Tregs were mainly responsible for the increase. The percentage of Tregs in TIM-3 high CD4 + T cells was lower than that in TIM-3 low CD4 + T cells, and the expression of CTLA-4 and IL-10 was lower in TIM-3 high Tregs than in the TIM-3 low Tregs in MRL/lpr mice. Blockade of TIM-3 in vivo significantly increased the Treg population and the expression of CTLA-4 and IL-10 in Tregs, thus relieving the LN symptoms and pathology in MRL/lpr mice. Additionally, bioinformatics analysis indicated that TIM-3 regulates Treg cells in LN mainly through cytokine–cytokine receptor interactions, the PI3K-Akt signaling pathway, the T cell receptor signaling pathway, Th17 cell differentiation and the FoxO signaling pathway. Together, our study has demonstrated that TIM-3 regulates Tregs in LN and that overexpression of TIM-3 in CD4 + T cells and Tregs leads to Treg quantity and quality deficiency in MRL/lpr mice. Blockade of TIM-3 protects against LN by expanding Tregs and enhancing their suppressive capacity. Finally, TIM-3 might be a potential therapeutic target for the treatment of LN.
pharmacology & pharmacy,immunology
What problem does this paper attempt to address?